Document Detail


Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.
MedLine Citation:
PMID:  12199669     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The present study was undertaken to evaluate stability, pharmacokinetic profile and efficacy of continuous infusion of 8Y in patients with different types of von Willebrand disease (vWD). Following reconstitution, 8Y levels of von Willebrand factor ristocetin cofactor (vWF:Rco), vWF antigen and factor VIII coagulant activity (FVIII:C) decreased to about 80% of the baseline levels; addition of low molecular weight heparin decreased the level of FVIII:C even further. Reconstituted 8Y was found to be sterile for up to 6 days postreconstitution. Ten vWD patients (four with type 2A, three with type 3, two with type 1 and one with 2N) underwent pharmacokinetic analysis. The recovery of vWF: RCo was significantly lower in patients with type 3 vWD (1.4 +/- 0.05% U(-1) kg(-1)) compared with that of the patients with types 1 (2.3 +/- 0.52% U(-1) kg(-1)) or 2A (2.0 +/- 0.06% U(-1) kg(-1)) vWD (P = 0.015). Type 3 vWD patients exhibited significantly higher vWF:RCo clearance (5.1 +/- 1.1 mL kg(-1) h(-1)) compared with that of patients with type 2A (2.8 +/- 0.7 mL kg(-1) h(-1)) and type 1 (2.6 +/- 1.0 mL kg(-1) h(-1)) vWD (P = 0.028). Accordingly, terminal half-life was lower in patients with type 3 vWD (8.0 +/- 0.6 h(-1)) compared with type 2A (12.7 +/- 5.9 h(-1)) or type 1 (14 +/- 1.2 h(-1)) vWD patients. Multimeric pattern of vWF from patients' plasma was similar to that of 8Y. In two patients treated with 8Y by continuous infusion for prevention or treatment of bleeding haemostasis was achieved. Thus, 8Y is suitable and haemostatically effective for continuous infusion treatment in patients with vWD.
Authors:
A Lubetsky; U Martinowitz; J Luboshitz; G Kenet; N Keller; I Tamarin; A Inbal
Related Documents :
16695929 - The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purin...
1412199 - Plasminogen activators and plasminogen activator inhibitor 1 before and after venous oc...
20028419 - Comparison of kaolin and tissue factor activated thromboelastography in haemophilia.
17116339 - Measurements of chromogranin b can serve as a complement to chromogranin a.
12199669 - Efficacy and safety of a factor viii-von willebrand factor concentrate 8y: stability, b...
12567199 - High factor viii and the risk of venous thromboembolism.
9725309 - Sonography of achilles tendon xanthomas in patients with heterozygous familial hypercho...
17284309 - Persistent hyperglycemia is an independent predictor of outcome in acute myocardial inf...
18672349 - Apoe epsilon4 is associated with postictal confusion in patients with medically refract...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  8     ISSN:  1351-8216     ISO Abbreviation:  Haemophilia     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-08-29     Completed Date:  2003-04-17     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  622-8     Citation Subset:  IM    
Affiliation:
Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel-Hashomer, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Blood Loss, Surgical / prevention & control
Drug Evaluation / methods*
Factor VIII / administration & dosage*,  analysis,  pharmacokinetics
Female
Humans
Infusions, Intravenous
Male
Middle Aged
Postoperative Hemorrhage / therapy
Postpartum Hemorrhage / therapy
Pregnancy
Pregnancy Complications, Hematologic / blood,  classification,  therapy
von Willebrand Diseases / blood,  classification,  therapy*
von Willebrand Factor / administration & dosage*,  analysis,  pharmacokinetics
Chemical
Reg. No./Substance:
0/factor VIII-von Willebrand factor concentrate 8Y; 0/von Willebrand Factor; 9001-27-8/Factor VIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Guidelines for the diagnosis and management of von Willebrand disease in Italy.
Next Document:  Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedure...